Gammaked can be administered either as an intravenous (IV) infusion by a healthcare professional or, for Primary Immunodeficiency, as a subcutaneous (SC) infusion by trained patients or caregivers at home.
Intravenous (IV) Administration:
- Preparation: Gammaked is supplied as a 10% liquid solution, ready to use. Visually inspect the solution for particulate matter and discoloration before administration; do not use if it is turbid or discolored. Bring the solution to room temperature before infusion. Do not dilute Gammaked with other intravenous fluids or medications; if dilution is necessary (rarely, for very small pediatric patients), only 5% Dextrose in Water (D5W) should be used.
- Procedure: Administered directly into a vein using an infusion pump.
- Infusion Rate: Infusion should start at a slow rate (e.g., 0.5 mL/kg/hour or 1 mg/kg/min for 30 minutes) and gradually increased if tolerated. Maximum infusion rates vary by indication and patient tolerance (e.g., up to 8 mg/kg/min or 5 mL/kg/hour for some indications). Slower rates are generally used for patients at risk of renal dysfunction or thrombosis.
- Dedicated Line: Use a separate IV line for Gammaked infusion. The line can be flushed with D5W or 0.9% Sodium Chloride for Injection.
Subcutaneous (SC) Administration (for Primary Immunodeficiency only):
- Preparation: Also a ready-to-use 10% liquid solution. Allow to reach room temperature before use.
- Procedure: Administered using a dedicated infusion pump into the subcutaneous tissue, typically at multiple sites (e.g., abdomen, thighs, upper arms). Patients or caregivers must receive comprehensive training from a healthcare professional on proper aseptic technique, equipment use, and site management for home infusions.
- Frequency: Usually administered weekly, but dosing frequency can be individualized.
- Site Rotation: Infusion sites must be rotated with each infusion to minimize local adverse reactions. Infusion sites should be at least 2 inches (5 cm) apart.
- Not for ITP or CIDP: SC administration is not approved for ITP or CIDP due to the potential risk of hematoma formation in ITP and the need for rapid systemic levels in CIDP often best achieved via IV.
The specific dose, frequency, and route of administration are determined by the healthcare provider based on the individual patient’s condition, body weight, and response to treatment.
Gammaked provides therapeutic benefits through two main mechanisms, depending on the condition being treated: passive immunization and immune modulation.
- Passive Immunization: In patients with Primary Immunodeficiency (PI), Gammaked directly replaces deficient IgG antibodies. These antibodies, collected from thousands of healthy donors, offer a wide range of specificities against various bacterial, viral, and other microbial pathogens. By providing these antibodies, Gammaked helps the body neutralize pathogens and toxins, enhancing the immune defense and reducing the risk of infection.
- Immune Modulation: In autoimmune and inflammatory conditions like Idiopathic Thrombocytopenic Purpura (ITP) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Gammaked works through complex immunomodulatory effects. While the exact mechanisms are not fully elucidated, they are thought to involve:
- Fc Receptor Blockade: The Fc (crystallizable) portion of the infused IgG can saturate Fc receptors on immune cells (e.g., macrophages, phagocytes). This prevents these cells from binding to and destroying autoantibody-coated platelets (in ITP) or nerve cells (in CIDP).
- Neutralization of Autoantibodies: The diverse pool of antibodies in Gammaked may contain anti-idiotypic antibodies that can bind to and neutralize disease-causing autoantibodies.
- Modulation of Cytokine and Chemokine Production: It can influence the production and activity of various pro-inflammatory and anti-inflammatory mediators, helping to restore immune balance.
- Complement System Inhibition: Gammaked can interfere with the activation of the complement cascade, which is involved in immune-mediated inflammation and tissue damage.
- Regulation of B and T Cells: It may affect the function, proliferation, and differentiation of B and T lymphocytes, crucial for adaptive immunity and autoimmune processes.
The route of administration (IV vs. SC) influences the pharmacokinetic profile, with IV administration leading to rapid high peak concentrations and SC administration resulting in more stable, sustained IgG levels.
Gammaked can cause side effects, which can vary in incidence and severity depending on the route of administration and individual patient factors. Most common reactions are mild and temporary, but serious adverse events can occur.
Common Side Effects:
- With IV Administration: Headache, fever, chills (rigors), fatigue, nausea, vomiting, dizziness, abdominal pain, muscle pain (myalgia), back pain, chest discomfort, cough, rash, pruritus (itching), flushing, blood pressure changes (increase or decrease). These are often infusion-related and may be managed by adjusting the infusion rate or with pre-medication.
- With SC Administration (primarily for PI): Local infusion site reactions are very common, including pain, swelling, redness (erythema), itching, bruising, and warmth at the injection site. These reactions are usually mild, localized, and resolve within a day. Systemic common side effects (e.g., headache, fatigue, nausea) tend to be less frequent or less severe compared to IV administration.
- Other Common (across both routes): Upper respiratory tract infection, pharyngitis, sinusitis.
Serious Side Effects (can occur with both IV and SC administration, but some more common with IV):
- Severe Hypersensitivity/Anaphylaxis: Rare but life-threatening allergic reactions, including severe hives, swelling of the face, throat, or tongue, severe difficulty breathing, wheezing, profound dizziness, chest pain, or loss of consciousness. The risk is higher in patients with total IgA deficiency who have antibodies to IgA.
- Acute Renal Dysfunction/Failure: Risk is elevated in predisposed patients (pre-existing kidney disease, diabetes, dehydration, advanced age, certain concomitant medications). Symptoms may include decreased urination or swelling.
- Thromboembolic Events (Blood Clots): Blood clots in the heart (myocardial infarction), brain (stroke), lungs (pulmonary embolism), or deep veins (DVT) can occur. Risk factors include advanced age, prolonged immobilization, hypercoagulable conditions, or a history of clots.
- Aseptic Meningitis Syndrome (AMS): A rare, non-infectious inflammation of the meninges, characterized by severe headache, stiff neck, fever, photophobia (light sensitivity), nausea, and vomiting.
- Hemolysis: Destruction of red blood cells, which can lead to anemia. Symptoms include dark urine, pale skin, or yellowing of skin/eyes.
- Transfusion-Related Acute Lung Injury (TRALI): A rare but severe lung complication with sudden onset of shortness of breath and hypoxemia.
- Volume Overload: Can occur, particularly with rapid or high-volume infusions in patients with underlying cardiac or renal compromise.
Any new, unusual, or worsening symptoms, especially severe ones, should be reported to the healthcare provider immediately.
Gammaked carries several important warnings and precautions that healthcare providers and patients must observe for safe use.
- Boxed Warning: Thrombosis, Renal Dysfunction, and Acute Renal Failure:
- Thrombosis (Blood Clots): Thrombosis may occur with immune globulin products, including Gammaked. Risk factors include advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors. Administer Gammaked at the minimum dose and infusion rate practicable for patients at risk. Ensure adequate hydration before administration.
- Renal Dysfunction and Acute Renal Failure: Acute renal dysfunction and failure can occur, particularly in predisposed patients (those with pre-existing renal insufficiency, diabetes mellitus, age >65, volume depletion, sepsis, paraproteinemia, or concomitant use of nephrotoxic drugs). Gammaked is sucrose-free, which may reduce this risk compared to sucrose-containing IVIG products, but adequate hydration and monitoring of renal function (BUN/creatinine) are still crucial.
- Hypersensitivity/Anaphylaxis: Gammaked is contraindicated in individuals with a history of anaphylactic or severe systemic reactions to human immune globulin. It is also contraindicated in IgA-deficient patients with antibodies to IgA and a history of hypersensitivity reaction due to the increased risk of severe anaphylaxis. Emergency medical support must be immediately available during administration.
- Aseptic Meningitis Syndrome (AMS): Patients should be monitored for signs and symptoms of AMS.
- Hemolysis: Gammaked contains blood group antibodies and can cause hemolysis. Patients should be closely monitored for clinical signs and symptoms of hemolysis and hemolytic anemia, especially those with non-O blood group or pre-existing anemia.
- Transfusion-Related Acute Lung Injury (TRALI): Monitor patients for pulmonary adverse reactions.
- Volume Overload: The high dose regimen (e.g., for ITP or CIDP loading) is not recommended for individuals with expanded fluid volumes or where fluid volume may be a concern (e.g., patients with cardiac impairment).
- Transmission of Infectious Agents: Because Gammaked is made from human plasma, it may carry a risk of transmitting infectious agents (e.g., viruses, variant Creutzfeldt-Jakob disease [vCJD] agent, and theoretically, the Creutzfeldt-Jakob disease [CJD] agent), despite extensive donor screening and viral inactivation/removal processes.
- Interference with Live Virus Vaccines: Gammaked can interfere with the development of immunity to live attenuated virus vaccines.
- Interference with Laboratory Tests: Passively transferred antibodies can lead to false-positive serological tests or interfere with certain laboratory assays.
- Hyperproteinemia, Increased Serum Viscosity, and Pseudohyponatremia: These can occur. Patients should be monitored for these changes, and pseudohyponatremia (false low sodium due to high protein) should be distinguished from true hyponatremia to avoid inappropriate fluid management.
- Hematoma Formation (SC Use in ITP): Gammaked is not approved for subcutaneous use in patients with ITP due to the potential risk of hematoma formation.
Gammaked, like other immune globulin products, can interact with certain medications, particularly affecting the efficacy of live virus vaccines and potentially increasing risks when used with nephrotoxic drugs.
- Live Virus Vaccines: The antibodies in Gammaked can interfere with the immune response to live attenuated virus vaccines (e.g., Measles, Mumps, Rubella [MMR], Varicella [chickenpox], Yellow Fever). Vaccination with such vaccines should generally be deferred for at least 6 months (and up to 11 months depending on the vaccine and Gammaked dose) after Gammaked administration. Always consult the prescribing information and your healthcare provider for specific vaccination recommendations.
- Nephrotoxic Drugs: Concomitant use with other medications known to cause kidney damage (nephrotoxic drugs) may increase the risk of acute kidney injury. Examples include certain antibiotics (e.g., aminoglycosides) or loop diuretics. Close monitoring of renal function is recommended when these drugs are co-administered.
- Interference with Laboratory Tests: Passively transferred antibodies from Gammaked can lead to false-positive serological test results (e.g., for certain viral infections) or interfere with specific assay readings, such as blood group antibody testing (Coombs’ test), potentially leading to misleading interpretations. This effect can persist for several months after the last infusion.
Patients should always inform their healthcare provider about all prescription medications, over-the-counter drugs, herbal remedies, and supplements they are taking to avoid potential interactions.
The dosage of Gammaked is highly individualized based on the specific indication, patient body weight, clinical response, and, for some conditions, targeted serum IgG trough levels.
- Intravenous (IV) Dosage:
- Primary Humoral Immunodeficiency (PI):
- Dose: Typically 300 to 600 mg/kg (0.3 to 0.6 g/kg) body weight, administered every 3 to 4 weeks.
- Adjustment: Dosage and frequency are adjusted based on the patient’s clinical response (e.g., reduction in infection rate) and to achieve desired IgG trough serum levels (often aiming for trough levels typically above 500-800 mg/dL).
- Infusion Rate: Initial rate usually 1 mg/kg/min (0.01 mL/kg/min) for 30 minutes. If tolerated, the rate can be gradually increased to a maximum of 8 mg/kg/min (0.08 mL/kg/min). For patients at risk of renal dysfunction or thrombosis, administer at the minimum practicable infusion rate.
- Idiopathic Thrombocytopenic Purpura (ITP):
- Dose: 2 g/kg (20 mL/kg) body weight, administered as a single dose. The dose may be divided into two 1 g/kg doses over 2 consecutive days. If an adequate increase in platelet count is observed after the first 1 g/kg dose, the second dose may be withheld.
- Infusion Rate: Initial rate 1 mg/kg/min, gradually increased to a maximum of 8 mg/kg/min if tolerated.
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP):
- Loading Dose: 2 g/kg (20 mL/kg) total dose, given in divided doses over 2 to 4 consecutive days.
- Maintenance Dose: 1 g/kg (10 mL/kg) every 3 weeks, given over 1 day or evenly divided over 2 consecutive days.
- Infusion Rate: Initial rate 2 mg/kg/min, gradually increased to a maximum of 8 mg/kg/min if tolerated.
- Subcutaneous (SC) Dosage (for PI only):
- Initial Weekly Dose (Conversion from IV): To calculate the initial weekly SC dose, multiply the previous total monthly IV dose in grams by a dose adjustment factor of 1.37, then divide by the number of weeks between doses during the patient’s IVIG treatment (i.e., 3 or 4 weeks). The goal is to achieve a systemic serum IgG exposure not inferior to that of the previous IVIG treatment.
- Maintenance Dose: Adjusted based on the patient’s clinical response and serum IgG trough levels.
- Frequency: Typically administered weekly.
- Infusion Rate/Volume per Site:
- Adults: Up to 8 infusion sites simultaneously; up to 30 mL/site at a rate of 20 to 30 mL/hour/site.
- Pediatric patients: Up to 6 infusion sites simultaneously; up to 20 mL/site (for body weight under 40 kg) or 30 mL/site (for body weight 40 kg and greater) at rates of 10-20 mL/hour/site depending on weight.
- Ensure infusion sites are at least 2 inches (5 cm) apart.
Gammaked is a prescription-only medication (POM). It is a highly specialized biological product requiring strict medical oversight.
- Specialist Prescribing: Gammaked must be prescribed by a licensed healthcare professional, typically an immunologist, neurologist, or hematologist, who has expertise in the diagnosis and management of the conditions for which it is indicated.
- Confirmed Diagnosis: A definitive medical diagnosis of Primary Immunodeficiency, Idiopathic Thrombocytopenic Purpura, or Chronic Inflammatory Demyelinating Polyneuropathy is required, supported by appropriate clinical and laboratory findings.
- Prior Authorization: Due to its significant cost and specific indications, Gammaked often requires prior authorization from insurance providers. This typically involves submitting detailed medical documentation to justify its necessity.
- Administration by Healthcare Professional (IV): For intravenous administration, Gammaked must be prepared and infused by trained healthcare professionals in a hospital, specialized infusion center, or qualified outpatient setting.
- Patient/Caregiver Training (SC for PI): For subcutaneous administration in Primary Immunodeficiency, patients or their caregivers must receive comprehensive training from a qualified healthcare professional (e.g., a specialized nurse) on aseptic technique, proper use of the infusion pump and supplies, site selection and rotation, and recognition and management of potential side effects before home administration.
- Comprehensive Monitoring: Patients receiving Gammaked require ongoing medical monitoring to assess both efficacy (e.g., IgG trough levels, neurological status, platelet counts) and safety (e.g., renal function, complete blood counts, and vigilance for infusion-related reactions or other serious adverse events).
- Blood Product Origin: As Gammaked is derived from human plasma, it falls under strict regulatory guidelines concerning donor screening and manufacturing processes to ensure safety. This further reinforces its prescription-only status.
